An Early Phase 1 interventional study of Larotrectinib and Cadonilimab in IDH Wildtype Glioblastoma and Glioblastoma (GBM), sponsored by Olivia Newton-John Cancer Research Institute. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Olivia Newton-John Cancer Research Institute · Early Phase 1, Interventional, and Treatment
This study will investigate whether rapid molecular testing of recurrent glioblastoma (GBM) can identify tumour biomarkers that may help guide treatment selection in younger people with IDH-wildtype GBM. Participants will be people under 55 years of age whose diagnosis is consistent with glioblastoma and who have undergone recent surgery or previously participated in the initial phase of the BRAid GBM study.
Tumour tissue will undergo rapid molecular testing to identify biomarkers that may predict response to specific targeted treatments. Treatment decisions will be informed by the molecular characteristics of each participant's tumour and available evidence for treatments associated with the identified biomarkers.
The study will assess the feasibility and safety of implementing rapid molecular testing across multiple Australian hospitals and whether this approach can provide timely information to support personalised treatment decisions. The study will also explore whether biomarker-guided treatment may provide alternatives to, or reduce the use of, radiotherapy in younger people with glioblastoma, with the potential to reduce long-term treatment-related effects on cognition and quality of life.
Approximately 110 patients will be screened and 12 participants will be recruited from participating hospitals across Australia.
The BRAid GBM study is evaluating a novel treatment approach for younger people (under 55 years of age) with glioblastoma (GBM), an aggressive form of brain cancer. Standard treatment for GBM generally involves surgery followed by radiotherapy and chemotherapy. Although this approach can help control the disease, radiotherapy can cause long-term effects on brain function, including difficulties with memory, thinking and concentration, which may significantly affect quality of life, work and family life.
A small proportion of glioblastomas harbour specific molecular alterations that may make the tumour susceptible to targeted therapies. These include alterations involving the BRAF and NTRK genes and deficiency of the mismatch repair (MMR) system. Targeted therapies directed at these molecular abnormalities have demonstrated clinical benefit in other cancers and, in some cases, in patients with brain tumours. The BRAid GBM study will investigate whether rapid molecular testing of tumour tissue obtained at surgery can identify these alterations and enable treatment to be selected according to the molecular characteristics of an individual's tumour.
Patients whose tumours harbour an actionable biomarker may receive a matched targeted therapy: plixorafenib for BRAF-altered tumours, larotrectinib for NTRK fusion-positive tumours, or cadonilimab for MMR-deficient tumours. Patients whose tumours do not demonstrate an eligible biomarker will proceed with standard treatment with radiotherapy and chemotherapy. This approach is intended to determine whether rapid molecular profiling can identify patients who may be suitable for an alternative treatment strategy while maintaining timely access to standard care when targeted treatment is not indicated.
Participants will undergo regular clinical assessments and MRI scans to monitor tumour response and disease progression, together with quality-of-life and cognitive assessments to evaluate the effects of treatment on neurological and functional outcomes. Blood and tumour samples will also be collected for translational research to investigate the biological characteristics of glioblastoma and factors that may influence treatment response or resistance.
2,132 studies on the registry are indexed under Glioblastoma; 464 are open to participants now.
This study's planned enrollment of 12 is below the median of 36 across 1,753 interventional studies indexed under Glioblastoma.
Browse Glioblastoma studies →Olivia Newton-John Cancer Research Institute is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Eligibility Criteria (Pre-Operative Screening)
Inclusion Criteria:
Exclusion Criteria:
Key Eligibility Criteria (Post-Operative Screening)
Inclusion Criteria:
Exclusion Criteria:
Key Eligibility Criteria (for patients being offered trial treatment)
Inclusion Criteria:
Adequate organ function as defined by
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plixorafenib 900 mg orally once daily continuously
Drug: Plixorafenib
Larotrectinib 100 mg orally twice daily continuously
Drug: Larotrectinib
Cadonilimab 6 mg/kg intravenously on Days 1 and 15
Drug: Cadonilimab
Larotrectinib is a first-in-class, highly selective, oral inhibitor of the tropomyosin receptor kinase (TRK) family of proteins (TRKA, TRKB and TRKC).
AK104 is bispecific IgG single chain Fv fragment (ScFv) monoclonal antibody that binds to human programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
Plixorafenib is a next generation, orally available, small-molecule, selective inhibitor of Class 1 and 2 mutated BRAF.
Feasibility of Rapid Molecular Profiling and Matched Targeted Therapy
To assess the feasibility of performing rapid molecular profiling before chemoradiation and initiating matched targeted therapy in patients with actionable molecular alterations.
Time frame: From enrollment to initiation of chemoradiation (pre-treatment period).
Number and Percentage of Participants Experiencing Adverse Events by CTCAE Grade
Toxicity of treatment with plixorafenib, cadonilimab, or larotrectinib will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. The number and percentage of participants experiencing adverse events will be summarized by CTCAE severity grade and, where applicable, relationship to study treatment.
Time frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 days after the end of study treatment.
Efficacy of Induction Targeted Therapy in Newly Diagnosed Glioblastoma
To assess the efficacy of induction treatment with plixorafenib, cadonilimab, or larotrectinib in patients with newly diagnosed glioblastoma and eligible molecular profiles, measured by progression-free survival (PFS) and time to next intervention (TTNI)
Time frame: From Cycle 1 Day 1 (each cycle is 28 days) until the commencement of the next anti-cancer intervention or death from any cause, whichever occurs first.
Change in Quality of Life Scores as Assessed by the EORTC QLQ-C30 Questionarrie
The effect of upfront treatment with plixorafenib, cadonilimab, or larotrectinib on quality of life in patients with newly diagnosed glioblastoma with eligible molecular phenotypes will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores will be calculated according to the questionnaire scoring manual.
Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through the end of treatment (EOT), up to 12 months.
Change in Learning and Memory Scores as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Neurocognitive function in patients with newly diagnosed glioblastoma and eligible molecular profiles will be assessed using the Hopkins Verbal Learning Test-Revised (HVLT-R), which evaluates verbal learning and memory.
Time frame: At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis.
Change in Quality of Life Scores as Assessed by the EORTC QLQ-BN20 Questionarrie
The effect of upfront treatment with plixorafenib, cadonilimab, or larotrectinib on brain tumour-specific quality of life in patients with newly diagnosed glioblastoma with eligible molecular phenotypes will be assessed using the European Organisation for Research and Treatment of Cancer Brain Neoplasm Module (EORTC QLQ-BN20). Scores will be calculated according to the questionnaire scoring manual.
Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through the end of treatment (EOT), up to 12 months.
Change in Attention and Working Memory Scores as Assessed by the Wechsler Adult Intelligence Scale Digit Span Test
Attention and working memory will be assessed using the Digit Span subtest of the Wechsler Adult Intelligence Scale (WAIS). Changes in scores from baseline will be summarized over the assessment period.
Time frame: At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis.
Change in Processing Speed as Assessed by Trail Making Test Part A
Processing speed will be assessed using Trail Making Test Part A. Changes in test performance from baseline will be summarized over the assessment period.
Time frame: At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis.
Change in Executive Function as Assessed by Verbal Fluency and Trail Making Test Part B
Executive function will be assessed using verbal fluency testing and Trail Making Test Part B. Changes in test performance from baseline will be summarized over the assessment period.
Time frame: At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis.
Overall Survival
Overall survival is defined as the time from Cycle 1 Day 1 (C1D1) to death from any cause. Overall survival will be summarized using the Kaplan-Meier method, with median overall survival and corresponding 95% confidence intervals reported, as applicable.
Time frame: From Cycle 1 Day 1 (each cycle is 28 days) until death from any cause or the end of the study follow-up period for a maximum of 5 years.
BRAF V600E, Mismatch Repair Protein, and Pan-TRK Expression Status in Glioblastoma Tissue Samples
Glioblastoma tissue samples from patients undergoing prescreening or screening will be analyzed for BRAF V600E and mismatch repair (MMR) protein expression using immunohistochemistry (IHC). BRAF V600E testing will use the VE1 monoclonal antibody. MMR protein testing will assess MSH2, MSH6, PMS2, and MLH1. Pan-TRK IHC will be performed using the EPR17341 antibody, with staining intensity scored according to the specified scoring system. Samples with a Pan-TRK IHC score of 3+ will undergo confirmatory next-generation sequencing (NGS) to identify TRK gene fusions. Results will be reported according to the relevant test findings, including biomarker status and confirmatory molecular results where applicable. Samples may also be stored and used for future unspecified translational research as outlined within the informed consent form.
Time frame: During prescreening or screening, before initiation of study treatment.
Translational Biomarker Analyses of Whole Blood, Plasma, Serum, and Peripheral Blood Mononuclear Cells
Translational blood samples, including whole blood (WB), plasma, serum, and peripheral blood mononuclear cells (PBMCs), will be collected for biomarker analyses related to treatment response and resistance in patients with newly diagnosed glioblastoma treated with plixorafenib, cadonilimab, or larotrectinib. Samples may also be stored and used for future unspecified translational research as outlined within the informed consent form.
Time frame: From baseline (before initiation of study treatment) through the treatment period and disease progression, total of 12 months.
Plan to share: No — Data sharing to occur at publication.
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Mar 2028, 12 months later.
Of 240 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 12 months is below that.
Counting every sponsor, half of 322 studies reached it within 44 months; a quarter within 29 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Larotrectinib · Cadonilimab · PLX8394
Olivia Newton-John Cancer Research Institute